Your browser doesn't support javascript.
loading
Intestinal fat absorption shifting: polyglucosamine biopolymer controls lipids and weight and reduces the progression of subclinical atherosclerosis.
Belcaro, Gianni; Cornelli, Umberto; Hosoi, Morio; Cox, David; Dugall, Mark; Cesarone, Maria R; Ledda, Andrea; Scipione, Valeria; Scipione, Claudia; Feragalli, Beatrice; Cotellese, Roberto.
Afiliación
  • Belcaro G; Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy - cardres@abol.it.
  • Cornelli U; Loyola University Medical School of Chicago, Chicago, IL, USA.
  • Hosoi M; Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy.
  • Cox D; Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy.
  • Dugall M; Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy.
  • Cesarone MR; Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy.
  • Ledda A; Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy.
  • Scipione V; Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy.
  • Scipione C; Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy.
  • Feragalli B; SMOBiotec Department, D'Annunzio University, Chieti, Chieti-Pescara, Italy.
  • Cotellese R; SMOBiotec Department, D'Annunzio University, Chieti, Chieti-Pescara, Italy.
Minerva Gastroenterol (Torino) ; 69(1): 114-122, 2023 Mar.
Article en En | MEDLINE | ID: mdl-36856275
BACKGROUND: Intestinal fat absorption shifting (IFAS) can be obtained in hyperlipidemic subjects with polyglucosamine biopolymer (BP) able to segregate most metabolic fats in the gut, making them unavailable for intestinal interaction (shift). The aim of this study was to evaluate the effects of a SM (standard management) for hyperlipidemia in asymptomatic subjects for primary cardiovascular prevention focusing on arterial wall morphology (IMT thickness) in comparison to SM associated to the administration of the BP. METHODS: Two groups of comparable subjects (SM and SM+oral BP, 3 g/day) were considered; subjects were managed - in a supplement, pilot registry - for a year. Weight, fat mass, lipid profile, oxidative stress, IMT (carotids), the presence of granulations at the internal arterial layers and "near wall low density 'bubbles' were observed and compared at 1 year of management. A non-parallel, comparable group of subjects (102) using a statin for the same conditions was used as a reference population. RESULTS: Two hundred eighty-four subjects completed one year (140 in the SM group and 144 in the SM+BP group). Compliance was optimal with (96.3% of the table correctly used) with no side effects. BMI, fat mass and oxidative stress decreased more in the SM+BP group (P<0.05). Cholesterol and triglycerides levels were significantly improved with BP (P<0.05). IMT measurements were significantly decreased (P<0.05) in the SM+BP group (as for the intimal granulation/bubbles) with minimal variations in the comparative SM group. In the statin group, the lipid profile was modified (P<0.05) but not the IMT and the rate of drop outs was higher (15.7%); these patients stopped the management; in 23% of these subjects muscular pain not seen with BP, was observed. CONCLUSIONS: These results indicate positive effects of IFAS due to BP on IMT and arterial wall morphology and weight after 12 months. Fat shifting at intestinal level and the reduction of oxidative stress limit lipid oxidation/deposition into the arterial wall.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Hidroximetilglutaril-CoA Reductasas / Aterosclerosis Límite: Humans Idioma: En Revista: Minerva Gastroenterol (Torino) Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Hidroximetilglutaril-CoA Reductasas / Aterosclerosis Límite: Humans Idioma: En Revista: Minerva Gastroenterol (Torino) Año: 2023 Tipo del documento: Article